临床癌症患者中伤害性与混合性疼痛的阿片类药物反应性比较
研究前瞻性收集240例使用阿片类药物的癌症疼痛患者数据,比较伤害性疼痛与混合性疼痛对阿片类药物的反应性。结果显示两组疼痛强度均显著且均匀降低,校正混杂因素后吗啡等效剂量对数变化及芬太尼血药浓度对数均与疼痛类型无显著关联。结论认为在临床癌症患者中,混合性疼痛对阿片类药物的反应性与伤害性疼痛相当。
要点
- 伤害性疼痛组173例与混合性疼痛组67例在入组至第3天疼痛强度均显著且均匀降低。
- 第3天吗啡等效剂量中位数伤害性疼痛组40 mg、混合性疼痛组40 mg,两组无显著差异。
- 校正混杂因素后,吗啡等效剂量变化对数及芬太尼血药浓度对数与疼痛类型无显著关联。
核心结论
- 至少在临床癌症患者中,混合性疼痛对阿片类药物的反应性与伤害性疼痛相当。
研究设计与样本
- 前瞻性收集240例使用阿片类药物的临床癌症疼痛患者数据。
- 采用多元线性回归评估入组第3天相较入组时的吗啡等效剂量对数变化(logRMED)与疼痛类型(伤害性 vs 混合性)的关联,并校正性别、年龄、原发癌部位及非阿片类和辅助镇痛药使用。
- 次要结局为第3天吗啡等效剂量对数(logMED)及芬太尼血药浓度对数(logPFent)与疼痛类型的关联。
主要发现
- 伤害性疼痛组(n=173)与混合性疼痛组(n=67)在入组至第3天疼痛强度均显著且均匀降低。
- 入组时吗啡等效剂量中位数(四分位距)伤害性疼痛组为20(10-52)mg,混合性疼痛组为20(20-80)mg;第3天分别为40(10-67)mg和40(20-100)mg,均无显著差异。
- 第3天芬太尼血药浓度中位数(四分位距)伤害性疼痛组为1.59(0.58-3.19)ng/ml,混合性疼痛组为1.38(0.54-4.39)ng/ml,无显著差异。
- 校正混杂因素后,logRMED、第3天logMED及第3天logPFent均与疼痛类型无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether clinical cancer patients with mixed nociceptive-neuropathic pain are less responsive to opioids than patients with nociceptive pain. BACKGROUND: Pain is common in advanced cancer patients. Pain driven by neuropathic mechanisms is considered to be resistant to opioids. This hypothesis is mainly based on animal studies and single-dose opioid studies in humans but has not been confirmed in clinical practice. METHODS: Data were prospectively collected from 240 clinical cancer pain patients using opioids. Multiple linear regression was used for assessing the associations between the logarithm of the morphine equivalent dose (MED) at three days after admission (T = 3d) relative to admission (T = 0d) (logRMED) and type of pain (nociceptive versus mixed pain), corrected for gender, age, primary cancer site and use of non-opioid and adjuvant analgesics. As secondary outcome measures, associations between logMED and logPFent (fentanyl plasma level) at T = 3d and type of pain were assessed. RESULTS: Pain intensity between T = 0d and T = 3d was significantly and evenly reduced in patients with nociceptive pain (n = 173) and mixed pain (n = 67). Median (interquartile range) MED was 20 (10-52) and 20 (20-80) mg (T = 0d), 40 (10-67) and 40 (20-100) mg (T = 3d), median PFent (T = 3d) was 1.59 (0.58-3.19) and 1.38 (0.54-4.39) ng/ml, none of them significantly different, in patients with nociceptive and mixed pain, respectively. Neither logRMED, logMED (T = 3d), or logPFent (T = 3d) was significantly associated with type of pain, after correction for confounding factors. CONCLUSIONS: We conclude that, at least in clinical cancer patients, mixed pain is as responsive to opioids as nociceptive pain.
引用
- Bechakra M, Moerdijk F, van Rosmalen J, et al. Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients. Eur J Cancer. 2018. PMID: 30439627. doi:10.1016/j.ejca.2018.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。